1 High-Flying Stock to Buy Hand Over Fist if the Stock Market Crashes

Source Motley_fool

Key Points

  • Moderna’s personalized cancer vaccine candidate, intismeran autogene, significantly reduced the risk of melanoma recurrence in a Phase 3 trial, a first for a personalized cancer vaccine.

  • But the stock has risen too much, too fast, and it’s worth waiting for a sell-off before initiating a position.

  • 10 stocks we like better than Moderna ›

Innovation often pays off. Moderna (NASDAQ:MRNA) has proven as much this year. The company's shares have soared in 2026 on the back of impressive clinical and regulatory progress. But is there any upside left for the vaccine maker? Not in my view. But Moderna would be a great stock to buy if the stock market crashes. Read on to find out more.

Red Moderna sign with blue accents on a modern building exterior

Image source: Getty Images.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

Moderna's impressive accomplishment

Moderna is pioneering mRNA-based personalized cancer vaccines. These products offer the potential to train patients' immune systems to recognize and destroy cancer cells based on specific mutations present in each patient's tumor. This approach could lead to much greater treatment efficacy than conventional cancer medicines. Personalized cancer vaccines may also more effectively prevent recurrence.

Moderna provided the first positive Phase 3 clinical trial data for an investigational personalized cancer vaccine, intismeran autogene, earlier this year. Moderna is developing intismeran autogene with Merck (NYSE:MRK), and in this Phase 3 study, the personalized cancer vaccine was tested as a combination therapy with Keytruda -- the best-selling cancer drug in the world -- versus Keytruda alone in certain patients with melanoma. Intismeran autogene, combined with Keytruda, led to meaningful improvements in recurrence-free survival. This clinical win sent Moderna's shares up by more than 100% overnight.

The price is not right

The market is seeing beyond Moderna's clinical win. The company proved that personalized cancer vaccines can reach significant clinical success. Intismeran autogene hasn't done so yet, but based on its Phase 3 results, it should eventually generate significant sales. Some analysts expect the personalized cancer vaccine to generate more than $10 billion in revenue at its peak, especially as it earns approvals across additional indications beyond melanoma.

It is being invested in as a treatment across several other forms of cancer. And the rest of the company's lineup and pipeline also looks robust. For instance, Moderna has earned approval for mFLUSIVA, an influenza vaccine, earlier this year. Its coronavirus vaccine is still on the market, and it is developing several other candidates in infectious diseases.

Some of the company's targets look ambitious. Moderna is developing a potential HIV vaccine, for instance. There is a long road ahead for this candidate, but if it is successful, it could be a game changer. That said, Moderna's most important strength isn't any single pipeline candidate or currently approved product.

It is the company's innovative mRNA-based platform that should produce significant clinical milestones over the next five to 10 years. However, there is a problem. The market may have already factored Moderna's success into its share price. Consider that the company's market cap is $82 billion, as of writing. Even assuming Moderna could generate $10 billion in sales next year (which it won't), it would be trading at 8.2x estimated 2027 sales, a fairly expensive valuation for a biotech stock of this size.

True, more clinical wins could jolt the stock, but even with that in mind, I am not convinced the valuation makes sense. After all, even intismeran autogene isn't approved yet, and some other advanced pipeline candidates may not earn U.S. approval for another two years. Adding commercial ramp-up times, we are looking at revenue far into the future even for the company's most advanced programs, and that's assuming they are successful at all.

The uncertainty of these future revenues (and cash flows) makes for a somewhat risky outlook at current levels: Too much could go wrong and sink the stock. I'd like a much more reasonable valuation and a significant margin of error -- considering we are discussing a volatile biotech stock -- before investing. If Moderna's market cap falls below $50 billion in a market crash, I'd definitely consider buying because the business looks strong, the science is impeccable, and the company's future looks bright.

But valuation is a major sticking point. I am keeping Moderna on my watch list for now.

Should you buy stock in Moderna right now?

Before you buy stock in Moderna, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Moderna wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $315,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $896,981!*

Now, it’s worth noting Stock Advisor’s total average return is 768% — a market-crushing outperformance compared to 198% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 20, 2026.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck and Moderna. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold Price Today: Can XAU/USD Hold $3,500? | Mitrade AUGold approaches US$3,500 as Fed tightening fears drive sharp weekly losses. Explore XAU/USD levels, Treasury yields and the outlook for Australian traders.
Author  Mitrade Team
10 hours ago
Gold approaches US$3,500 as Fed tightening fears drive sharp weekly losses. Explore XAU/USD levels, Treasury yields and the outlook for Australian traders.
placeholder
Australia’s jobs market just cracked — has the AUD/USD rate story flipped?Australia’s weakening jobs market is raising fresh questions about the RBA’s interest rate outlook and the Australian dollar. Explore why AUD/USD could be losing support, the key factors driving currency movements and what Australian forex traders should watch next.
Author  Mark Garro
15 hours ago
Australia’s weakening jobs market is raising fresh questions about the RBA’s interest rate outlook and the Australian dollar. Explore why AUD/USD could be losing support, the key factors driving currency movements and what Australian forex traders should watch next.
placeholder
Market News Today Australia: VIX Surges Nearly 16%, Gold Breaks US$3,600 and US Stocks SlideVIX jumps 15.8%, Nasdaq 100 falls 2.21% and gold slips below US$3,600. Explore Anthropic’s debut and the outlook for Australian CFD traders.
Author  Mitrade Team
16 hours ago
VIX jumps 15.8%, Nasdaq 100 falls 2.21% and gold slips below US$3,600. Explore Anthropic’s debut and the outlook for Australian CFD traders.
placeholder
Is Tech in a Bear Market? 20 Tech Stocks Fall Up to 76% From HighsAll 20 tech stocks on a list from financial newsletter The Kobeissi Letter trade at least 25% below record highs. CoreWeave (CRWV) leads the slide at 76%.Additionally, the S&P 500 has lost over $6 tri
Author  Beincrypto
16 hours ago
All 20 tech stocks on a list from financial newsletter The Kobeissi Letter trade at least 25% below record highs. CoreWeave (CRWV) leads the slide at 76%.Additionally, the S&P 500 has lost over $6 tri
placeholder
Gold and Bitcoin Are Falling. Peter Schiff Sees Opportunities for BothPeter Schiff says gold should not have fallen at all, while Bitcoin (BTC) has not fallen enough. The gold advocate calls the metal’s drop a buying opportunity and Bitcoin’s a selling opportunity.Both
Author  Beincrypto
16 hours ago
Peter Schiff says gold should not have fallen at all, while Bitcoin (BTC) has not fallen enough. The gold advocate calls the metal’s drop a buying opportunity and Bitcoin’s a selling opportunity.Both
goTop
quote